Participated · Series C · Dec 2025

AngelEye Health develops a suite of software and hardware tools—such as secure livestream cameras, MilkTracker feeding management, NICU2Home discharge planning, and the forthcoming AIVision analytics module—that modernize neonatal and pediatric inpatient care. Its platform supports real-time family engagement, automates documentation, and delivers AI-powered insights to care teams. The company’s solutions are deployed in more than 350 hospitals, touching roughly 20 % of NICU families across the United States. AngelEye has earned four consecutive spots on the Inc. 5000 list and recently achieved SOC II Type 2 compliance. With the new capital, the team plans to accelerate AIVision’s commercialization and broaden its U.S. sales footprint. Although specific revenue figures were not disclosed, the company positions itself as a trusted partner in patient safety, operational efficiency, and family empowerment within NICUs and PICUs.

Participated · Series A · Jan 2024

Clarametyx Biosciences is a clinical-stage biotechnology company developing immune-enabling therapies and vaccines to address biofilm-driven chronic respiratory diseases. Its lead program, CMTX-101, is an investigational antibody therapy designed to rapidly destroy the pro-inflammatory structure of bacterial biofilms to enhance antibiotic and immune efficacy and is being developed in cystic fibrosis. CMTX-101 is in a Phase 1b/2a trial evaluating safety, tolerability, pharmacokinetics, immunogenicity and reduction of pulmonary Pseudomonas aeruginosa burden; an interim analysis of the first 21 participants met prespecified criteria to proceed. The company is also advancing an anti-biofilm vaccine, CMTX-301, in early development and is pursuing lead optimization toward a 2027 IND. Clarametyx has closed an upsized second tranche of its Series A financing from existing investors to support ongoing pipeline activities for both therapeutic and vaccine programs. The Phase 1b/2a study is on track for full enrollment by the end of 2025, and additional participants and sites will be added. The company is based in Columbus, Ohio. Clarametyx Biosciences develops a technology platform that targets bacterial biofilms to enable a more effective immune response and antibiotic interventions. The company is building a pipeline of immune-enabling therapies and vaccines for serious bacterial infections associated with biofilms, with a near-term focus on chronic respiratory diseases. Its lead programs include CMTX-101, currently in a trial for cystic fibrosis–related infections conducted in collaboration with the Cystic Fibrosis Foundation, and CMTX-301, a vaccine program recently funded by CARB-X. The company is clinical stage and led by CEO David Richards. Clarametyx intends to use new funding to accelerate the ongoing CMTX-101 trial and advance development of CMTX-301. The company is based in Columbus, OH. Clarametyx Biosciences is a clinical-stage company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with bacterial biofilms. Launched in 2020 to advance an antibody technology licensed from Nationwide Children’s Hospital, the platform is non-antibiotic and pathogen-agnostic, designed to target and remove universal structural elements within biofilms to induce rapid biofilm collapse. Its lead candidate, CMTX-101, is being developed as an adjunct to standard-of-care antibiotics to render bacteria vulnerable to immune or antibiotic intervention. The company is evaluating its anti-biofilm technology in both therapeutic and preventive settings and is building a pipeline with a near-term focus on challenging respiratory infections. Clarametyx has initiated a Phase 1b/2a trial in people with cystic fibrosis to assess safety, tolerability, PK, immunogenicity, reduction of pulmonary P. aeruginosa burden, and exploratory endpoints (ClinicalTrials.gov identifier NCT06159725). The recently completed $33 million Series A will fund accelerated pipeline work and expanded clinical evaluations; the company is based in Columbus, Ohio. Clarametyx Biosciences is developing a platform that targets the biofilm matrix to remove a universal, pathogen-agnostic target, collapsing the protective shield and rendering bacteria vulnerable to immune and antibiotic attack. Its lead candidate, CMTX-101, is a humanized monoclonal antibody in preclinical development with a first targeted indication of moderate-to-severe or hospital-acquired pneumonia. The company is advancing IND-enabling activities including a GLP toxicity study and Phase 1 material production, with plans to initiate first-in-human clinical trials later this year. Financially, Clarametyx has received earlier CARB-X awards in 2020 and 2021 and was recently awarded an additional $3.89 million in option funding to accelerate development of CMTX-101. Under the CARB-X agreement the company is eligible for one further funding option to support a first-in-human trial, contingent on milestone achievement and competitive positioning. Clarametyx is building a broader pipeline of immune-enabling therapies and vaccines for life-threatening infections associated with biofilms. Clarametyx Biosciences is a preclinical-stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent, biofilm-associated bacterial infections. Its platform is designed to precisely remove a universal, pathogen-agnostic target within the biofilm extracellular matrix, rapidly collapsing the protective shield and sensitizing bacteria to immune and antibiotic attack. The approach aims to enhance innate immune activity and sensitize a wide range of Gram-negative and Gram-positive pathogens to first-line and other antibiotics, enabling potential therapeutics and vaccines. Lead candidate CMTX-101 is a humanized monoclonal antibody in preclinical development for hospital-acquired, moderate-to-severe pneumonia to be co-administered with standard antibiotic regimens. Clarametyx was awarded up to $14.2 million from CARB-X to advance its platform through completion of a Phase 1 clinical study, with a $2.4M base period and three milestone-based options. The company is based in Columbus, Ohio and is building a pipeline of immune-enabling therapies and vaccines for life-threatening infections associated with biofilms.